SEC Form 6-K filed by Trinity Biotech plc
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, County Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On October 7, 2024, the Company issued a press release
announcing positive pre-pivotal trial results for its next-generation continuous glucose monitor (CGM) technology. The press release is furnished herewith as Exhibit 99.1.
EXHIBIT INDEX
|
Exhibit
|
Description
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
TRINITY BIOTECH PLC
|
|||
|
Trinity Biotech plc
|
|||
|
(Registrant)
|
|||
|
By:
|
/s/ Louise Tallon
|
||
|
Louise Tallon
|
|||
|
Chief Financial Officer
|
|||
Date: October 7, 2024